Soligenix to Present at Spartan Capital's Inaugural Investor Conference in New York

Soligenix, Inc., a late-stage biopharmaceutical company focusing on rare diseases, has announced its participation in Spartan Capital Securities, LLC's inaugural investor conference at the Pierre Hotel in New York on November 4th. This event provides a significant platform for the company to present its achievements and future plans to influential figures in capital markets, as stated by Christopher J. Schaber, PhD, President and CEO of Soligenix. The conference, organized in partnership with B2i Digital, will feature presentations from over 30 carefully selected companies and aims to foster high-level investor engagement through panel discussions, one-on-one meetings, and networking sessions.

Soligenix's involvement in this conference is particularly important due to the company's focus on developing and commercializing products for rare diseases with unmet medical needs. The company's Specialized BioTherapeutics segment is advancing HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma, toward potential commercialization following the successful completion of a second Phase 3 study. This positions Soligenix to seek regulatory approvals for worldwide commercialization, which could address significant gaps in treatment options for patients with this condition.

Beyond HyBryte™, Soligenix is developing other promising therapies, including synthetic hypericin for psoriasis and dusquetide for inflammatory diseases such as oral mucositis in head and neck cancer. The company's Public Health Solutions segment is also progressing with vaccine candidates for ricin toxin, filoviruses, and COVID-19, utilizing its proprietary ThermoVax® heat stabilization platform technology. These developments underscore the broader implications of Soligenix's work, which extends beyond rare diseases to include public health threats and common inflammatory conditions.

The conference itself represents a strategic opportunity for Soligenix to maximize exposure to potential investors and industry partners, as highlighted by John D. Lowry, Founder and CEO of Spartan Capital Securities, LLC. Lowry noted that the event commemorates Spartan Capital's 17 years as a trusted leader in capital markets and emphasizes the firm's commitment to building meaningful connections between client companies and sophisticated investors. For investors and industry observers, Soligenix's participation offers insights into the company's progress and potential, especially as the biopharmaceutical sector evolves and requires innovative funding and partnership models.

Events like this play a crucial role in connecting innovative companies with the capital and collaborations necessary to bring new treatments to market, particularly in the competitive and high-stakes arena of rare disease therapies. As Soligenix advances its pipeline, this conference may serve as a pivotal moment in the company's journey toward commercializing much-needed therapies. More information about the conference and registration details is available on Spartan Capital's conference page, providing a resource for those interested in the broader context of investor engagement in the biopharmaceutical industry.